Congress Clears Path for ACT for ALS Reauthorization

The legislation, designated H.R. 8205, emerged from a coordinated push led by Representatives Mike Quigley and Ken Calvert alongside Senators Lisa Murkowski and Chris Coons. The passage prevents a critical lapse in funding for programs that support patients unable to participate in traditional clinical trials. For a disease characterized by rapid progression and limited treatment options, the continuity of these research streams is essential.

ALS Network president and CEO Sheri Strahl credited the victory to the persistent engagement of the patient community. Advocates across the country utilized direct meetings, emails, and personal testimonials to maintain legislative momentum. The organization played a central role in these efforts, providing policy recommendations and mobilizing support on Capitol Hill to secure the necessary bipartisan backing. Once signed into law, the act will sustain existing frameworks for biomarker research and shared data resources, while extending benefits that reach beyond ALS to other rare neurodegenerative conditions.